Evomela
Plasma Cell Leukemia
National Cancer Institute (NCI)Phase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 73/ 100
Competitive context
40 Active assets in the Plasma Cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | BB |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 3 | B |
cc-5013 National Cancer Institute (NCI) | Phase 3 | B |
DARATUMUMAB National Cancer Institute (NCI) | Phase 3 | B |
View all 50 →
Same molecule, other indications
Evomela is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →